Coronavirus vaccine

US12186387B2 · kind B2 · utility

Assignee

• BIONTECH SE · DE

Inventors

• Alexander Muik · Seeheim-Jugenheim, DE
• Asaf Poran · Stoneham, US
• Kena Anne Swanson · Pearl River, US
• Qi Yang · The Woodlands, US
• Hui-Zhi Cai · Ridgewood, US
• Ugur Sahin · Mainz, DE

Key dates

• Filing date: Nov 29, 2022
• Grant date: Jan 7, 2025
• Expiry date: Nov 29, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/20071
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-COV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-COV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.